Abstract
The in vitro susceptibilities of 102 human campylobacter strains isolated between 1978 and 1980 and 100 strains isolated in 1990 to ciprofloxacin, norfloxacin, erythromycin, gentamicin, and doxycycline were examined. The biotypes and heat-stable serotypes of the strains as well as antimicrobial treatments and travel history of the campylobacter-positive patients were also studied. The results indicated that susceptibility to erythromycin, gentamicin, and doxycycline has remained the same during the past 10 years. No gentamicin-resistant strains were found. Resistance to erythromycin was 3% in both groups of strains. However, the number of norfloxacin-resistant strains increased from 4 to 11% in the follow-up period, and ciprofloxacin-resistant strains, which had not occurred 10 years ago, composed 9% of the strains isolated in 1990. Thus, the increase of fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli has been significant in Finland in the past 10 years.
Full text
PDF![2065](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4514/245327/2af6f4571076/aac00054-0155.png)
![2066](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4514/245327/438e3855f7cc/aac00054-0156.png)
![2067](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4514/245327/a10dce861983/aac00054-0157.png)
![2068](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4514/245327/d0ab7729208a/aac00054-0158.png)
![2069](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4514/245327/420a0fa81370/aac00054-0159.png)
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Andreasen J. J. In vitro susceptibility of Campylobacter jejuni and Campylobacter coli isolated in Denmark to fourteen antimicrobial agents. Acta Pathol Microbiol Immunol Scand B. 1987 Jun;95(3):189–192. doi: 10.1111/j.1699-0463.1987.tb03110.x. [DOI] [PubMed] [Google Scholar]
- Brumfitt W., Franklin I., Grady D., Hamilton-Miller J. M., Iliffe A. Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. Antimicrob Agents Chemother. 1984 Nov;26(5):757–761. doi: 10.1128/aac.26.5.757. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dupont H. L., Corrado M. L., Sabbaj J. Use of norfloxacin in the treatment of acute diarrheal disease. Am J Med. 1987 Jun 26;82(6B):79–83. doi: 10.1016/0002-9343(87)90624-3. [DOI] [PubMed] [Google Scholar]
- Endtz H. P., Ruijs G. J., van Klingeren B., Jansen W. H., van der Reyden T., Mouton R. P. Quinolone resistance in campylobacter isolated from man and poultry following the introduction of fluoroquinolones in veterinary medicine. J Antimicrob Chemother. 1991 Feb;27(2):199–208. doi: 10.1093/jac/27.2.199. [DOI] [PubMed] [Google Scholar]
- Ericsson C. D., Johnson P. C., Dupont H. L., Morgan D. R., Bitsura J. A., de la Cabada F. J. Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers' diarrhea. A placebo-controlled, randomized trial. Ann Intern Med. 1987 Feb;106(2):216–220. doi: 10.7326/0003-4819-106-2-216. [DOI] [PubMed] [Google Scholar]
- Fliegelman R. M., Petrak R. M., Goodman L. J., Segreti J., Trenholme G. M., Kaplan R. L. Comparative in vitro activities of twelve antimicrobial agents against Campylobacter species. Antimicrob Agents Chemother. 1985 Mar;27(3):429–430. doi: 10.1128/aac.27.3.429. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Goodman L. J., Trenholme G. M., Kaplan R. L., Segreti J., Hines D., Petrak R., Nelson J. A., Mayer K. W., Landau W., Parkhurst G. W. Empiric antimicrobial therapy of domestically acquired acute diarrhea in urban adults. Arch Intern Med. 1990 Mar;150(3):541–546. [PubMed] [Google Scholar]
- Goossens H., De Mol P., Coignau H., Levy J., Grados O., Ghysels G., Innocent H., Butzler J. P. Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU28965 (a new macrolide), and other agents against enteropathogens. Antimicrob Agents Chemother. 1985 Mar;27(3):388–392. doi: 10.1128/aac.27.3.388. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gootz T. D., Martin B. A. Characterization of high-level quinolone resistance in Campylobacter jejuni. Antimicrob Agents Chemother. 1991 May;35(5):840–845. doi: 10.1128/aac.35.5.840. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hirschl A. M., Wolf D., Berger J., Rotter M. L. In vitro susceptibility of Campylobacter jejuni and Campylobacter coli isolated in Austria to erythromycin and ciprofloxacin. Zentralbl Bakteriol. 1990 Apr;272(4):443–447. doi: 10.1016/s0934-8840(11)80045-9. [DOI] [PubMed] [Google Scholar]
- Johnson P. C., Ericsson C. D., Morgan D. R., Dupont H. L., Cabada F. J. Lack of emergence of resistant fecal flora during successful prophylaxis of traveler's diarrhea with norfloxacin. Antimicrob Agents Chemother. 1986 Nov;30(5):671–674. doi: 10.1128/aac.30.5.671. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lariviere L. A., Gaudreau C. L., Turgeon F. F. Susceptibility of clinical isolates of Campylobacter jejuni to twenty-five antimicrobial agents. J Antimicrob Chemother. 1986 Dec;18(6):681–685. doi: 10.1093/jac/18.6.681. [DOI] [PubMed] [Google Scholar]
- Lähdevirta J. Ciprofloxacin in the elimination of enteric Salmonella carriage stage. Scand J Infect Dis Suppl. 1989;60:112–115. [PubMed] [Google Scholar]
- Olsson-Liljequist B., Möllby R. In vitro activity of norfloxacin and other antibacterial agents against gastro-intestinal pathogens isolated in Sweden. APMIS. 1990 Feb;98(2):150–155. doi: 10.1111/j.1699-0463.1990.tb01015.x. [DOI] [PubMed] [Google Scholar]
- Penner J. L., Hennessy J. N., Congi R. V. Serotyping of Campylobacter jejuni and Campylobacter coli on the basis of thermostable antigens. Eur J Clin Microbiol. 1983 Aug;2(4):378–383. doi: 10.1007/BF02019474. [DOI] [PubMed] [Google Scholar]
- Pichler H. E., Diridl G., Stickler K., Wolf D. Clinical efficacy of ciprofloxacin compared with placebo in bacterial diarrhea. Am J Med. 1987 Apr 27;82(4A):329–332. [PubMed] [Google Scholar]
- Rademaker C. M., Hoepelman I. M., Wolfhagen M. J., Beumer H., Rozenberg-Arska M., Verhoef J. Results of a double-blind placebo-controlled study using ciprofloxacin for prevention of travelers' diarrhea. Eur J Clin Microbiol Infect Dis. 1989 Aug;8(8):690–694. doi: 10.1007/BF01963753. [DOI] [PubMed] [Google Scholar]
- Rautelin H. I., Renkonen O. V., von Bonsdorff C. H., Lähdevirta J., Pitkänen T., Järvinen A., Reinikainen P., Kosunen T. U. Prospective study of the etiology of diarrhea in adult outpatients and inpatients. Scand J Gastroenterol. 1989 Apr;24(3):329–333. doi: 10.3109/00365528909093055. [DOI] [PubMed] [Google Scholar]
- Reina J., Alomar P. Fluoroquinolone-resistance in thermophilic Campylobacter spp isolated from stools of Spanish patients. Lancet. 1990 Jul 21;336(8708):186–186. doi: 10.1016/0140-6736(90)91715-m. [DOI] [PubMed] [Google Scholar]
- Secker D. A. Erythromycin resistance only found in Campylobacter coli. J Antimicrob Chemother. 1983 Oct;12(4):414–415. doi: 10.1093/jac/12.4.414. [DOI] [PubMed] [Google Scholar]
- Skirrow M. B. A demographic survey of campylobacter, salmonella and shigella infections in England. A Public Health Laboratory Service Survey. Epidemiol Infect. 1987 Dec;99(3):647–657. doi: 10.1017/s0950268800066504. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Skirrow M. B., Benjamin J. Differentiation of enteropathogenic Campylobacter. J Clin Pathol. 1980 Nov;33(11):1122–1122. doi: 10.1136/jcp.33.11.1122. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Skirrow M. B. Campylobacter enteritis: a "new" disease. Br Med J. 1977 Jul 2;2(6078):9–11. doi: 10.1136/bmj.2.6078.9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Svedhem A., Kaijser B. Campylobacter fetus subspecies jejuni: a common cause of diarrhea in Sweden. J Infect Dis. 1980 Sep;142(3):353–359. doi: 10.1093/infdis/142.3.353. [DOI] [PubMed] [Google Scholar]
- Taylor D. E., Courvalin P. Mechanisms of antibiotic resistance in Campylobacter species. Antimicrob Agents Chemother. 1988 Aug;32(8):1107–1112. doi: 10.1128/aac.32.8.1107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Taylor D. E., Ng L. K., Lior H. Susceptibility of Campylobacter species to nalidixic acid, enoxacin, and other DNA gyrase inhibitors. Antimicrob Agents Chemother. 1985 Nov;28(5):708–710. doi: 10.1128/aac.28.5.708. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Vanhoof R., Gordts B., Dierickx R., Coignau H., Butzler J. P. Bacteriostatic and bactericidal activities of 24 antimicrobial agents against Campylobacter fetus subsp. jejuni. Antimicrob Agents Chemother. 1980 Jul;18(1):118–121. doi: 10.1128/aac.18.1.118. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Walder M. Susceptibility of Campylobacter fetus subsp. jejuni to twenty antimicrobiol agents. Antimicrob Agents Chemother. 1979 Jul;16(1):37–39. doi: 10.1128/aac.16.1.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wang W. L., Reller L. B., Blaser M. J. Comparison of antimicrobial susceptibility patterns of Campylobacter jejuni and Campylobacter coli. Antimicrob Agents Chemother. 1984 Sep;26(3):351–353. doi: 10.1128/aac.26.3.351. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wiström J., Norrby S. R., Burman L. G., Lundholm R., Jellheden B., Englund G. Norfloxacin versus placebo for prophylaxis against travellers' diarrhoea. J Antimicrob Chemother. 1987 Oct;20(4):563–574. doi: 10.1093/jac/20.4.563. [DOI] [PubMed] [Google Scholar]
- von Graevenitz A. Revised nomenclature of Campylobacter laridis, Enterobacter intermedium, and "Flavobacterium branchiophila". Int J Syst Bacteriol. 1990 Apr;40(2):211–211. doi: 10.1099/00207713-40-2-211. [DOI] [PubMed] [Google Scholar]